Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of Budenofalk granules and capsules for acute Crohn's disease
NL-OMON24660Not yet recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of budesonide in Crohn's disease, sponsored by Dr. Falk Pharma GmbH. Planned start Nov 2016; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON24660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24660.